Filtered By:
Condition: Heart Failure
Countries: Switzerland Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 51 results found since Jan 2013.

Aetiological blood biomarkers of ischaemic stroke.
We describe the potential role of 22 selected blood biomarkers in the context of stroke aetiology. Finally we provide the readers with an outlook in this research field. PMID: 26024210 [PubMed - as supplied by publisher]
Source: Swiss Medical Weekly - May 31, 2015 Category: Journals (General) Authors: Sonderer JB, Katan M Tags: Swiss Med Wkly Source Type: research

Napping Once Or Twice A Week Could Lower Heart Attack & Stroke Risk, Study Finds
By Amy Woodyatt, CNN (CNN) — Some good news for nap fanatics — a new study has found that a daytime nap taken once or twice a week could lower the risk of heart attacks or strokes. Researchers from the University Hospital of Lausanne, Switzerland studied the association between napping frequency and duration and the risk of fatal and non-fatal cardiovascular disease complications. Tracking 3,462 people between the ages of 35 and 75 for just over five years, the report authors found that those who indulged in occasional napping — once or twice a week, for between five minutes to an hour — were 48% ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 10, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Heart Attack Stroke Source Type: news

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Long-Term Exposure to Road Traffic Noise and Nitrogen Dioxide and Risk of Heart Failure: A Cohort Study
Conclusions: Long-term exposure to NO2 and road traffic noise was associated with higher risk of heart failure, mainly among men, in both single- and two-pollutant models. High exposure to both pollutants was associated with highest risk. https://doi.org/10.1289/EHP1272 Received: 25 October 2016 Revised: 09 August 2017 Accepted: 09 August 2017 Published: 26 September 2017 Address correspondence to M. Sørensen. Diet, Genes and Environment, Danish Cancer Society, Strandboulevarden 49, 2100 Copenhagen, Denmark. Telephone: +45 35257626. Email: mettes@cancer.dk Supplemental Material is available online (https://doi.org/1...
Source: EHP Research - September 26, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Combination of Dexmedetomidine and Ketamine for Magnetic Resonance Imaging Sedation
Conclusions: The efficacy of DEX–KET sedation was comparable to that of midazolam for MRI examination. DEX–KET was related to shorter scan time and lower occurrence of complications compared to midazolam. Introduction Neurocritically ill patients often require brain magnetic resonance imaging (MRI) in addition to conventional neurological evaluations. Brain MRI can reveal structural lesions with a high sensitivity due to its excellent spatial resolution and enhanced soft tissue contrast (1–3). To acquire MRI images, patients' cooperation is imperative. However, keeping patients with ...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

Godly gift for arthritis pain
Big Pharma is at it again… Creating and selling a drug that causes thousands of heart attacks and strokes each year. In 2015, the FDA asked drug makers to strengthen their warning labels. Since then, most have listed their dangerous side effects on the bottle. But one manufacturer thought they didn’t have to warn people about their dangerous drug. They marketed their product as a “unique” breakthrough. They even published studies promising it was “safe for long-term use.” 1 The drug is a 7-year-old arthritis drug called Actemra. It’s made by the Swiss pharmaceutical company Roche. ...
Source: Al Sears, MD Natural Remedies - October 5, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

Patterns of incidence rates of cardiac complications in patients with congenital heart disease
ConclusionsCardiac complications are frequent in congenital heart disease. Apart from perioperative stroke and complete heart block, incidence rates are low in childhood but the incidence increases during adult life. These data underscore the need of life-long follow up and may help for better allocation of resources maintaining follow-up.
Source: Canadian Journal of Cardiology - October 4, 2018 Category: Cardiology Source Type: research

Association of pulmonary vein isolation and major cardiovascular events in patients with atrial fibrillation
ConclusionsIn our matched comparison, patients in the PVI group had a lower incidence rate of all-cause mortality and hospital admission for acute heart failure compared to the non-PVI group.ClinicalTrials.gov IdentifierNCT02105844, April 7th 2014.Graphical abstract
Source: Clinical Research in Cardiology - April 11, 2022 Category: Cardiology Source Type: research

Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.
CONCLUSIONS: PIVOTAL will provide important information about the optimum dosing of IV iron in HD patients representative of usual clinical practice. TRIAL REGISTRATION: EudraCT number: 2013-002267-25. PMID: 30304714 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - October 10, 2018 Category: Urology & Nephrology Authors: Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Steenkamp R, Tomson CRV, Wheeler DC, Winearls CG, Ford I, on behalf of the PIVOTAL Trial investigators Tags: Am J Nephrol Source Type: research

Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial
Publication date: Available online 27 September 2019Source: The LancetAuthor(s): Jonas Lanz, Won-Keun Kim, Thomas Walther, Christof Burgdorf, Helge Möllmann, Axel Linke, Simon Redwood, Christian Thilo, Michael Hilker, Michael Joner, Holger Thiele, Lars Conzelmann, Lenard Conradi, Sebastian Kerber, Gerhard Schymik, Bernard Prendergast, Oliver Husser, Stefan Stortecky, Dik Heg, Peter JüniSummaryBackgroundTranscatheter aortic valve replacement (TAVR) is the preferred treatment option for older patients with symptomatic severe aortic stenosis. Differences in the properties of available TAVR systems can affect clinical outcom...
Source: The Lancet - September 28, 2019 Category: General Medicine Source Type: research

Atrial fibrillation for internists: current practice.
Abstract Atrial fibrillation (AF) has become a global epidemic and puts affected patients at high risk of adverse events. In this review we summarise the current evidence on risk factors and complications of AF, describe current treatment strategies, and outline new fields of research. Current evidence shows that hypertension and obesity are the two most important modifiable risk factors for the development of AF. Patients with AF face an increased stroke risk. Oral anticoagulation reduces this risk substantially. Mainly for reasons of safety and ease of use, non-vitamin K antagonist oral anticoagulants are prefer...
Source: Swiss Medical Weekly - March 8, 2020 Category: General Medicine Authors: Meyre P, Conen D, Osswald S, Kühne M, Meyer-Zürn C Tags: Swiss Med Wkly Source Type: research

Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news